Research ArticleOriginal Article
Open Access

Side-effects of COVID-19 vaccines among the Saudi population

A cross-sectional study

Ebtehaj S. Almughais, Ali H. Alharbi, Hadi A. Aldarwish, Areeb F. Alshammari, Razan S. Alsuhaymi, Jumanah A. Almuaili and Atheer M. Alanizy
Saudi Medical Journal April 2022, 43 (4) 386-393; DOI: https://doi.org/10.15537/smj.2022.43.4.20210905

References

  1. 1.↵
    1. Yüce M,
    2. Filiztekin E,
    3. Özkaya KG.
    COVID-19 diagnosis —A review of current methods. Biosens Bioelectron 2021; 172: 112752.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kaur SP,
    2. Gupta V.
    COVID-19 Vaccine: A comprehensive status report. Virus Res 2020; 288: 198114.
    OpenUrlCrossRefPubMed
  3. 3.↵
    World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. [Updated 2022 March 2; Cited 2021 May 16]. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_02March2022.pdf
  4. 4.↵
    1. Voysey M,
    2. Clemens SAC,
    3. Madhi SA,
    4. Weckx LY,
    5. Folegatti PM,
    6. Aley PK, et al.
    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Centers fir Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events. [Updated 2021 November 5; Cited 2021 Jul 14]. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity
  6. 6.↵
    Ministry of Health. COVID-19 Vaccine. [Updated 2021 June 14; Cited 2021 Jul 12]. Available from: https://www.moh.gov.sa/en/eServices/Pages/Covid19-egistration.aspx
  7. 7.↵
    1. Alabdulla M,
    2. Reagu SM,
    3. Al-Khal A,
    4. Elzain M,
    5. Jones RM.
    COVID-19 vaccine hesitancy and attitudes in Qatar: A national cross-sectional survey of a migrant-majority population. Influenza Other Respir Viruses 2021; 15: 361–370.
    OpenUrlCrossRef
  8. 8.↵
    1. Alibrahim J,
    2. Awad A.
    COVID-19 vaccine hesitancy among the public in Kuwait: A cross-sectional survey. Int J Environ Res Public Health 2021; 18: 8836.
    OpenUrl
  9. 9.↵
    1. Dror AA,
    2. Eisenbach N,
    3. Taiber S,
    4. Morozov NG,
    5. Mizrachi M,
    6. Zigron A, et al.
    Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol 2020; 35: 775–779.
    OpenUrlPubMed
  10. 10.↵
    1. Riad A,
    2. Pokorná A,
    3. Attia S,
    4. Klugarová J,
    5. Koščík M,
    6. Klugar M.
    Prevalence of COVID-19 Vaccine side effects among healthcare workers in the Czech Republic. J Clin Med 2021; 10: 1428.
    OpenUrl
  11. 11.↵
    1. Zhu FC,
    2. Li YH,
    3. Guan XH,
    4. Hou LH,
    5. Wang WJ,
    6. Li JX, et al.
    Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395: 1845–1854.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Kadali RAK,
    2. Janagama R,
    3. Peruru S,
    4. Malayala S V.
    Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis 2021; 106: 376–381.
    OpenUrlCrossRefPubMed
  13. 13.
    U.S. Food & Drug Administration. Fact Sheet For Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (Eua) Of The Pfizer-Biontech Covid-19 Vaccine To Prevent Coronavirus Disease 2019 (COVID-19). [Updated 2022 January 31; Cited 2021 Jul 23]. https://labeling.pfizer.com/ShowLabeling.aspx?id=14471&format=pdf
  14. 14.↵
    1. Abu-Hammad O,
    2. Alduraidi H,
    3. Abu-Hammad S,
    4. Alnazzawi A,
    5. Babkair H,
    6. Abu-Hammad A, et al.
    Side effects reported by jordanian healthcare workers who received Covid-19 vaccines. Vaccines 2021; 9: 577.
    OpenUrl
  15. 15.↵
    1. Xia S,
    2. Zhang Y,
    3. Wang Y,
    4. Wang H,
    5. Yang Y,
    6. Gao GF, et al.
    Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021; 21: 39–51.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Ramasamy MN,
    2. Minassian AM,
    3. Ewer KJ,
    4. Flaxman AL,
    5. Folegatti PM,
    6. Owens DR, et al.
    Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021 19; 396: 1979–1993.
    OpenUrl
  17. 17.
    1. Polack FP,
    2. Thomas SJ,
    3. Kitchin N,
    4. Absalon J,
    5. Gurtman A,
    6. Lockhart S, et al.
    Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–2615.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Mazur M,
    2. Duś-Ilnicka I,
    3. Jedliński M,
    4. Ndokaj A,
    5. Janiszewska-Olszowska J,
    6. Ardan R, et al.
    Facial and oral manifestations following covid-19 vaccination: A survey-based study and a first perspective. Int J Environ Res Public Health 2021; 18: 4965.
    OpenUrl
  19. 19.↵
    1. El-Shitany NA,
    2. Harakeh S,
    3. Badr-Eldin SM,
    4. Bagher AM,
    5. Eid BG,
    6. Almukadi HS, et al.
    Minor to moderate side effects of Pfzer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study retrospective cross-sectional study. Int J Gen Med 2021; 14: 1389–1401.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Menni C,
    2. Klaser K,
    3. May A,
    4. Polidori L,
    5. Capdevila J,
    6. Louca P, et al.
    Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect 2021; 21: 939–949.
    OpenUrl
  21. 21.↵
    1. Browne SK,
    2. Beeler JA,
    3. Roberts JN.
    Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants. Vaccine 2020; 38: 101–106.
    OpenUrl
  22. 22.↵
    1. Di Resta C,
    2. Ferrari D,
    3. Viganò M,
    4. Moro M,
    5. Sabetta E,
    6. Minerva M, et al.
    The gender impact assessment among healthcare workers in the sars-cov-2 vaccination—an analysis of serological response and side effects. Vaccines (Basel) 2021; 9: 522.
    OpenUrl
  23. 23.↵
    1. Menni C,
    2. Klaser K,
    3. May A,
    4. Polidori L,
    5. Capdevila J,
    6. Louca P, et al.
    Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021; 21: 939–949.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Watanabe M,
    2. Balena A,
    3. Tuccinardi D,
    4. Tozzi R,
    5. Risi R,
    6. Masi D, et al.
    Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev 2022; 38: e3465.
    OpenUrl
  25. 25.↵
    1. Choi WS,
    2. Cheong HJ.
    COVID-19 vaccination for people with comorbidities. Infect Chemother 2021; 53: 155–158.
    OpenUrl
  26. 26.↵
    1. Almufty HB,
    2. Mohammed SA,
    3. Abdullah AM,
    4. Merza MA.
    Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr 2021; 15: 102207.
    OpenUrl
  27. 27.↵
    1. Wise J.
    Covid-19: People who have had infection might only need one dose of mRNA vaccine. BMJ (Clinical research ed) 2021; 372: n308.
    OpenUrlFREE Full Text
  28. 28.↵
    1. Krammer F,
    2. Srivastava K,
    3. Alshammary H,
    4. Amoako AA,
    5. Awawda MH,
    6. Beach KF, et al.
    Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 2021; 384: 1372–1374.
    OpenUrlPubMed
  29. 29.↵
    1. Riad A,
    2. Sağıroğlu D,
    3. Üstün B,
    4. Pokorná A,
    5. Klugarová J,
    6. Attia S, et al.
    Article prevalence and risk factors of coronavac side effects: An independent cross-sectional study among healthcare workers in turkey. J Clin Med 2021; 10: 2629.
    OpenUrl
  30. 30.↵
    1. Manisty C,
    2. Otter AD,
    3. Treibel TA,
    4. McKnight Á,
    5. Altmann DM,
    6. Brooks T, et al.
    Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 2021; 397: 1057–1058.
    OpenUrl
  31. 31.
    1. Suresh P,
    2. Petchey W.
    ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Rep 2021; 14: e243931.
    OpenUrlPubMed
  32. 32.↵
    1. Hatmal MM,
    2. Al-Hatamleh MAI,
    3. Olaimat AN,
    4. Hatmal M,
    5. Alhaj-Qasem DM,
    6. Olaimat TM, et al.
    Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines 2021; 9: 556.
    OpenUrl
  33. 33.↵
    1. Funk CD,
    2. Laferrière C,
    3. Ardakani A.
    Target product profile analysis of covid-19 vaccines in phase iii clinical trials and beyond: An early 2021 perspective. Viruses 2021; 13: 418.
    OpenUrl
  34. 34.↵
    1. Vitiello A,
    2. Ferrara F.
    Brief review of the mRNA vaccines COVID-19. Inflammopharmacology 2021; 29: 645–649.
    OpenUrl
  35. 35.↵
    Centers fir Disease Control and Prevention. Possible Side Effects After Getting a COVID-19 Vaccine. [Updated 2022 Jan 12; Cited 2021 Aug 14]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/
  36. 36.↵
    1. Oliver SE,
    2. Gargano JW,
    3. Marin M,
    4. Wallace M,
    5. Curran KG,
    6. Chamberland M, et al.
    The Advisory Committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine — United States, December 2020. MMWR 2022; 69: 1922–1924.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords